Project Grant R37CA299472
Award Date
8/1/25
Completion Date
7/31/30
Dollars Obligated
$735K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $279,411 to the University of Washington to conduct research on the impact of breast cancer treatment on cardiovascular health and exercise capacity. The key activities under this award include: Quantifying epigenetic changes (DNA CpG site methylation) during breast cancer treatment and evaluating the association between epigenetic aging,...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Beckman Research Institute of the City of Hope provides $178,000.00 to evaluate the ELF5 clock as a novel biomarker for breast cancer prevention trials. The goal is to assess the ELF5 clock, which measures biological age in breast tissue, as a predictor of risk reduction in breast cancer prevention interventions. The project will (1) retrospectively evaluate the ELF5 clock...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $123,182 to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The funding supports research to understand the mechanisms by which dormant breast cancer cells communicate with their environment, including how obesity can reawaken these dormant cells and lead to metastatic relapse. Key focus areas include defining the regulatory network controlling...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), provides $577,529 to Health Research, Inc. to investigate the relationship between accelerated ribosomal DNA (rDNA) methylation age and early-onset prostate cancer in African American patients. The main objectives are to: 1) determine if African American prostate cancer patients exhibit higher rDNA methylation age at diagnosis compared to age-matched...
This Project Grant award from the National Cancer Institute (CFDA 93.396, Cancer Biology Research) provides $680,334 to the Icahn School of Medicine at Mount Sinai to conduct research aimed at understanding the fundamental biological mechanisms underlying age-associated pathogenic myelopoiesis and its contribution to increased cancer risk and progression in aging populations. The 5-year study will utilize high-dimensional profiling, multi-omics phenotyping, and complex bone marrow experiments to...
The National Cancer Institute (NCI) awarded a $510,431 Project Grant under the Cancer Biology Research (CFDA 93.396) program to The Johns Hopkins University. The grant, effective July 1, 2025 through June 30, 2030, supports comprehensive research to investigate the fundamental biological mechanisms underlying tumor dormancy, metastatic recurrence, and therapeutic resistance in aging melanoma patients. The research aims to uncover how the aging immune microenvironment influences tumor cell...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $388,750 to The Washington University to conduct research on the role of senescent cancer-associated fibroblasts (senCAFs) in breast cancer progression. The key objectives are to: 1) Determine the organ-specific effects of senCAFs on metastatic breast cancer progression; 2) Examine how senCAFs impact extracellular matrix dynamics and tumor cell migration; and 3) Assess the impact of senCAFs on...
The National Cancer Institute (NCI) awarded a $547,945 Project Grant under CFDA 93.396 (Cancer Biology Research) to The Johns Hopkins University to conduct research on the pathogenesis of immune checkpoint inhibitor-induced myocarditis. The project aims to investigate how biological factors such as prior cardiac injury, age, and sex modulate the risk of this adverse event, which occurs in 1-2% of cancer patients receiving immune checkpoint inhibitor therapy but can be fatal in up to 50% of...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) provides $204,474 to The Regents of the University of Colorado to conduct research aimed at defining the relationship between cell quiescence and senescence. The project will use advanced microscopy techniques and RNA sequencing to study the molecular mechanisms that mediate the transition from a reversible quiescent state to permanent cell cycle arrest, or senescence. The research...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $624,000.00 to the University of Texas Health Science Center at Houston to explore a patient priorities care framework for improving breast cancer survivorship care for older women with multiple chronic conditions. The project aims to use this framework to identify patient priorities, incorporate them into treatment plans, and evaluate the feasibility and impact on treatment burden and quality...